Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Rachel Thijssen, Sarah T. Diepstraten, Donia M. Moujalled, et al.
Blood (2021) Vol. 137, Iss. 20, pp. 2721-2735
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Sarah T. Diepstraten, Mary Ann Anderson, Peter E. Czabotar, et al.
Nature reviews. Cancer (2021) Vol. 22, Iss. 1, pp. 45-64
Closed Access | Times Cited: 257
Apoptotic cell death in disease—Current understanding of the NCCD 2023
Ilio Vitale, Federico Pietrocola, Emma Guilbaud, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 5, pp. 1097-1154
Open Access | Times Cited: 213
BCL2 and MCL1 inhibitors for hematologic malignancies
Andrew W. Roberts, Andrew H. Wei, David C.S. Huang
Blood (2021) Vol. 138, Iss. 13, pp. 1120-1136
Open Access | Times Cited: 144
Recent advances in targeted therapies in acute myeloid leukemia
Rahul S. Bhansali, Keith W. Pratz, Catherine Lai
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 123
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine
Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 24, pp. 5272-5279
Open Access | Times Cited: 101
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Naval Daver, Abhishek Maiti, Tapan M. Kadia, et al.
Cancer Discovery (2022) Vol. 12, Iss. 11, pp. 2516-2529
Open Access | Times Cited: 96
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Blood Cancer Discovery (2023) Vol. 4, Iss. 4, pp. 276-293
Open Access | Times Cited: 73
Structures of p53/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity
Hudie Wei, Haolan Wang, Genxin Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 49
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
Donia M. Moujalled, Fiona C. Brown, Chong Chyn Chua, et al.
Blood (2022) Vol. 141, Iss. 6, pp. 634-644
Open Access | Times Cited: 63
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia
Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 8, pp. 1035-1043
Closed Access | Times Cited: 62
Venetoclax resistance: mechanistic insights and future strategies
Faustine Ong, Kunhwa Kim, Marina Konopleva
Cancer Drug Resistance (2022) Vol. 5, Iss. 2, pp. 380-400
Open Access | Times Cited: 61
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study
Curtis A. Lachowiez, Patrick K. Reville, Hagop M. Kantarjian, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 5, pp. e350-e360
Open Access | Times Cited: 45
Targeting MCL-1 protein to treat cancer: opportunities and challenges
Shady I. Tantawy, Natalia Timofeeva, Aloke Sarkar, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 29
AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
Elisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Cancer (2023) Vol. 129, Iss. 7, pp. 992-1004
Open Access | Times Cited: 26
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
Zilu Wang, Huimin Hu, Luuk Heitink, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 4, pp. 1033-1046
Open Access | Times Cited: 23
TP53 in MDS and AML: Biological and clinical advances
Yeqian Zhao, Weihao Chen, Jing Yu, et al.
Cancer Letters (2024) Vol. 588, pp. 216767-216767
Closed Access | Times Cited: 14
Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
Sarah T. Diepstraten, Yuan Yin, John E. La Marca, et al.
Cancer Cell (2024) Vol. 42, Iss. 5, pp. 850-868.e9
Open Access | Times Cited: 12
Venetoclax Resistance in Acute Myeloid Leukemia
Sylvain Garciaz, Marie‐Anne Hospital, Yves Collette, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1091-1091
Open Access | Times Cited: 11
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Jan Mueller, Roman R. Schimmer, Christian Koch, et al.
EMBO Molecular Medicine (2024) Vol. 16, Iss. 3, pp. 445-474
Open Access | Times Cited: 10
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
Meike Vogler, Yannick Braun, Victoria M. Smith, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
Thomas E. Lew, John F. Seymour
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 37
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022
Gregory W. Roloff, Olatoyosi Odenike, Ashish Bajel, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 568-583
Open Access | Times Cited: 32
Mechanisms of venetoclax resistance and solutions
Jiachen Liu, Yidong Chen, Lihua Yu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?
Prajwal Dhakal, Melissa L. Bates, Michael H. Tomasson, et al.
Blood Reviews (2022) Vol. 59, pp. 101036-101036
Closed Access | Times Cited: 30
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
Bing Z. Carter, Po Yee Mak, Wenjing Tao, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top